The mission of Dr. Barry Sherman Institute for Medicinal Chemistry is to advance basic research insights for the benefit of therapeutic discoveries. Medicinal chemistry is a multidisciplinary research field at the crossroads of organic chemistry, pharmacology, and biology. It focuses on the identification, development, and evaluation of compounds for use as therapeutic agents using new technologies and screening techniques.
The Dr. Barry Sherman Institute for Medicinal Chemistry funds innovative research on compounds that hold promise for becoming therapies for a range of human diseases and disorders, including autoimmune diseases, cancer, neurodegenerative diseases and infectious diseases.
Director
Dr. Sarel Fleishman studies the way protein function is encoded in the structures of protein binders, enzymes, and antibodies. He computationally designs new protein functions not seen in Nature and experimentally characterizes these designs in order to examine them in the world. Among his honors are postdoctoral fellowships and a career development award from the Human Frontier Science Program, and the GE & Science Prize for Young Life Scientists.